Guangzhou Baiyunshan Jingxiutang Pharmaceutical Co. Ltd.December 8, 2023

FDA 483 - Guangzhou Baiyunshan Jingxiutang Pharmaceutical Co. Ltd. - December 08, 2023

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Guangzhou Baiyunshan Jingxiutang Pharmaceutical Co. Ltd.

Record Details

An FDA inspection of Guangzhou Baiyunshan Jingxiutang Pharmaceutical Co. Ltd., an OTC human drug manufacturer, revealed significant deficiencies in laboratory controls, including a repeat observation regarding active ingredient testing and inadequate microbial testing of the water system. Additionally, the firm failed to provide continuous GMP training to employees on US regulatory requirements, specifically 21 CFR Parts 210 and 211.

Company: Guangzhou Baiyunshan Jingxiutang Pharmaceutical Co. Ltd.
Inspection Date: December 8, 2023
Product Type: Drugs
Office: Office of Biological Products Operations - Division I
Person: Wayne D. Mcgrath

Open in Dashboard

ID · 5a459c98-5659-41ba-9a22-cd027b5cc931